Interventional Studies
What are Clinical Trials?
Clinical trials are studies that test new medications in people. Doctors use clinical trials to discover new treatments for diseases. New treatments are possible only through the voluntary participation of patients and family members. Research and Clinical Trials opportunities may be available.
MAEVE Study
Study Title: Microbiota Mediated Flavonoid Metabolites for Cognitive Health (MAEVE) Study
Purpose
The Microbiota Mediated Flavonoid Metabolites for Cognitive Health (MAEVE) study is a multi-center, randomized, double-blind, placebo-controlled study for cognitively normal older adults at enhanced risk of developing Alzheimer’s Disease (AD). The study seeks to enroll individuals who are aged 50+, and have an immediate family member with AD. Those who participate will have:
- 4 in-person appointments over 1 year. Visits include MRIs, cognitive testing, and blood draws.
- Monthly online questionnaires
- Nutritionist consults
(Principal Investigator: Arpana Church, PhD)
Contact: Marika Dy at (310) 267-0089 or ChurchLab@mednet.ucla.edu to participate in this study or for more information.
IRB Protocol IRB#24-0113
Novartis Study
Study Title: A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension (Novartis Study)
Purpose
The Novartis study seeks adults aged 50 to 85 to participate in a clinical trial evaluating whether VHB937 is safe and beneficial in people with early Alzheimer’s disease (AD). The study will assess the safety of VHB937 and its effects on memory and other cognitive abilities, daily activities, and brain changes. This medication targets neuroimmune pathways in early AD. The study will involve approximately 407 participants from research sites across 15 countries. UCLA aims to recruit 7 participants.
Participants will:
- Receive VHB937 or placebo via intravenous infusions monthly for 1.5 years during the double-blind period
- Participants who are enrolled in Part 1 will be randomly assigned study drug or placebo at a 4:1 ratio
- Participants who are enrolled in Part 2 will be randomly assigned study drug or placebo at a 2:1 ratio
- Receive VBH937 via intravenous infusions monthly for up to 6 years during the open-label extension period
- Undergo various research assessments, including medical history review, physical and neurological examinations, blood draws, memory tests, and brain scans.
- Need to have a study partner (i.e., relative, friend, caregiver) to accompany the participant for study visits.
(PI: Marie Kim, MD, PhD, Easton Center's Katherine and Benjamin Kagan Alzheimer's Disease Treatment Development Program)
Contact: Kagan Clinical Trials Program at (310) 794-6191 or send an email to EastonClinicalTrials@mednet.ucla.edu to participate in this study or for more information.
More information on the Novartis Study is available at clinicaltrials.gov ID#: NCT07094516.
PROMIS-AD Study
Study Title: Protocol for Maintaining and Improving Mental Status in Alzheimer’s Disease (PROMIS-AD) - a Pilot Study of Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer's Disease
Purpose
In this clinical trial, we are testing the effectiveness of repetitive Transcranial Magnetic Stimulation (TMS) on the treatment of Alzheimer’s Disease. We welcome English-speaking individuals age 55 to 100 years old with an Alzheimer’s Disease diagnosis to enroll. Participants will receive either active or sham TMS, and those who receive sham stimulation may be eligible to receive open-label active treatment after the completion of the study. Participation in the study would last up to 9 weeks for those receiving active stimulation and up to 18 weeks for those receiving sham.
(PI: Michael Leuchter, MD)
Contact: Griffin Bohman or Ellie Pinkerton at tmsresearch@mednet.ucla.edu or call (310) 825-4781 to participate or for more information.
IRB Protocol IRB#20-1417
More information on the PROMIS-AD study is available at clinicaltrials.gov ID#: NCT06597942.